NuGenerex Immuno-Oncology, Inc.

OTCPK:NUGX Stock Report

Market Cap: US$10.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NuGenerex Immuno-Oncology Management

Management criteria checks 1/4

Key information

Joe Moscato

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Joe Moscato (58 yo)

no data

Tenure

Mr. Joseph Moscato, also known as Joe, serves as Chief Executive Officer, President and Chairman of the Board at NuGenerex Immuno-Oncology, Inc. Mr. Moscato serves a s Chief Business Development Officer of...

Board Members

NamePositionTenureCompensationOwnership
Joseph Moscato
CEO, President & Chairmanno datano datano data
Anthony Crisci
Corporate Counselno datano datano data
Richard Purcell
Executive VP of R&D and Directorno datano datano data
Marvin Hausman
Independent Director3.4yrsno datano data
Carol Nacy
Independent Director3.3yrsno datano data
Brian McGee
Independent Directorno datano datano data
Sue Eckhardt
Independent Director3.2yrsno datano data
Craig Eagle
Member of Scientific & Clinical Advisory Board and Independent Director3.3yrsno datano data
Thomas Leonard
Independent Director3.3yrsno datano data
Jonathan Davis
Member of Scientific & Clinical Advisory Boardno datano datano data
Tamera Coyne-Beasley
Member of Scientific & Clinical Advisory Board2.6yrsno datano data
Thomas Rogers
Member of Scientific & Clinical Advisory Boardno datano datano data

3.3yrs

Average Tenure

61yo

Average Age

Experienced Board: NUGX's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/24 06:45
End of Day Share Price 2023/05/17 00:00
Earnings2021/04/30
Annual Earnings2020/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NuGenerex Immuno-Oncology, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.